|
Healthcare Headlines |
|
Muscular Dystrophy / ALS News From Medical News Today
|
-
News From The American Chemical Society, Nov. 19, 2008
Microcapsules act as "roach motel" to kill harmful bacteria Researchers in New Mexico and Florida are reporting development of microscopic particles that act as chemical booby traps for bacteria. The traps attract and kill up to 95 percent of nearby bacteria, including microbes responsible for worrisome hospital-based infections. The scientists describe their discovery as micro-sized "roach motels" for harmful bacteria.
-
Neurons Derived From Embryonic Stem Cells Restore Muscle Function After Injury
Dalhousie Medical School researchers have discovered that embryonic stem cells may play a critical role in helping people with nerve damage and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), regain muscular strength. Motor neurons reside in the spinal cord and control limb movements by enabling muscles to contract. Diseases like ALS cause them to degenerate, resulting in muscle weakness, atrophy, and eventual paralysis.
-
New Compounds Aimed At Muscular Dystrophy
Scientists have identified a promising set of new compounds in the fight against muscular dystrophy. Using a drug-discovery technique in which molecules compete against each other for access to the target the strand of toxic RNA that causes the most common form of muscular dystrophy in adults a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.
-
Nutra Pharma Announces Provision Of RPI-78M Under Compassionate Release To Adrenomyeloneuropathy (AMN) Patients
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, will provide RPI-78M under compassionate release to patients previously enrolled in the Phase IIb/IIIa clinical study of Adrenomyeloneuropathy (AMN).
-
Access To Specialist Care Breakthrough With Minister
Last week, the Muscular Dystrophy Campaign and leading clinicians were delighted to meet with senior Health Minister Lord Darzi. Lord Darzi has offered to work with the Muscular Dystrophy Campaign to improve access to specialist care and implement standards of care for all neuromuscular conditions.
|
|
